CAR-M2 immunotherapy resolves renal fibrosis via revascularization and apoptosis of profibrotic Cxcr2+ endothelial cells - PubMed
3 hours ago
- #renal fibrosis
- #CAR-M2 immunotherapy
- #Cxcr2+ endothelial cells
- CAR-M2 immunotherapy targets fibrotic niche to treat renal fibrosis.
- CAR-M2 uses HAMA-CS hydrogel for local delivery, reducing fibrosis and promoting revascularization.
- Identified profibrotic Cxcr2+ endothelial cells; their depletion mitigates fibrosis.
- Mechanism involves CAR-M2 releasing MMP2 to activate Rxra in Cxcr2+ ECs, inducing mitochondrial autophagy and apoptosis.